Video

ASH 2022: Recent Advances in Chronic Myeloid Leukemia

Author(s):

Sameem Abedin, MD,Elias Jabbour, MD

Experts in hematologic oncology review and analyze updated data in chronic myeloid leukemia from ASH 2022.

Data from the following clinical trials are discussed:

  • 620: Three-Year Update from the OPTIC Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib
  • 333: Outcome of Third-Line Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in Chronic Phase: A Propensity Score Analysis
  • 3009: Molecular Response of ≤10% BCR::ABL1IS Is Predictive of Positive Outcomes in Treatment-Resistant Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Ponatinib from the Phase 2 Optic Trial
  • 4339: Outcomes in Patients with Chronic Myeloid Leukemia in the Chronic Phase Randomized to Dasatinib or Imatinib after Suboptimal Responses to 3 Months of Imatinib Therapy: Final 5-Year Results from DASCERN

Supported in part by Amgen Oncology, Servier, and Takeda Oncology. Content developed independently by OncLive®.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Latest CME

View All
Navigating the Glaucoma Therapeutic and Surgical Landscape: From Conventional to Cutting-Edge
Video

Navigating the Glaucoma Therapeutic and Surgical Landscape: From Conventional to Cutting-Edge

May 14th 2025 - May 15th 2026

online-activity
View More
Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Arizona
Video

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Arizona

May 13th 2025 - Jun 18th 2025

online-activity
View More
16th Annual International Symposium on Ovarian Cancer and Other Gynecological Malignancies™
Video

16th Annual International Symposium on Ovarian Cancer and Other Gynecological Malignancies™

May 9th 2025 - Jun 14th 2025

online-activity
View More
Related Content
Peter WT Pisters, MD, MD Anderson Cancer Center
May 16th 2025

UT MD Anderson and Texas Children’s Hospital announce $150 Million Gift From Kinder Foundation to Launch Kinder Children’s Cancer Center

Shubham Pant, MD, MBBS, professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center; Professor Timothy Elliott, Kidani Professor of Immuno-oncology, Nuffield Department of Medicine, the University of Oxford
May 15th 2025

Cancer Vaccines Shake Up Disease Management and Prevention Strategies: With Shubham Pant, MD, MBBS; and Professor Timothy Elliott

Severe Aplastic Anemia | Image Credit: © alionaprof – stock.adobe.com
May 14th 2025

Generic Eltrombopag Is Now Available for Severe Aplastic Anemia and Immune Thrombocytopenia

Chandler Park, MD, medical oncologist, Norton Cancer Institute; Ann S. LaCasce, MD, MMSc, associate professor, medicine, lymphoma specialist, Dana-Farber Cancer Institute, Director, Dana-Farber/Mass General Brigham Fellowship in Hematology/Oncology
March 26th 2025

Strong Mentorship Opportunities Support the Next Generations of Women in Lymphoma: With Chandler Park, MD; and Ann S. LaCasce, MD, MMSc

The Inflation Reduction Act Affects Oncology | Image credit: © Valeri Luzina – stock.adobe.com
May 9th 2025

Inflation Reduction Act Leads to Seesaw Effect Between Oncologic Drug Savings and Development

FDA
May 8th 2025

FDA Lifts Clinical Hold on Tabelecleucel Trial for EBV+ Post-Transplant Lymphoproliferative Disease